Barclays PLC Replimune Group, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Barclays PLC holds 158,491 shares of REPL stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

158,491

Previous 158,491 -0.0%

Holding current value

$2.28 Million

Previous $1.74 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$8.09 - $11.23 $799,219 - $1.11 Million	98,791 Added 165.48%	158,491 $1.74 Million
Q2 2024 Aug 14, 2024	SELL	$5.01 - $9.46 $244,638 - $461,931	-48,830 Reduced 44.99%	59,700 $538,000
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $1.25 Million - $1.69 Million	-181,974 Reduced 62.64%	108,530 $885,000
Q4 2023 Feb 15, 2024	BUY	$6.75 - $16.18 $1.16 Million - $2.78 Million	172,092 Added 145.33%	290,504 $2.45 Million
Q3 2023 Nov 07, 2023	BUY	$15.96 - $22.18 $86,199 - $119,794	5,401 Added 4.78%	118,412 $2.03 Million
Q2 2023 Aug 03, 2023	BUY	$15.65 - $24.1 $336,193 - $517,716	21,482 Added 23.47%	113,011 $2.62 Million
Q1 2023 May 04, 2023	BUY	$17.48 - $29.09 $758,369 - $1.26 Million	43,385 Added 90.12%	91,529 $1.62 Million
Q4 2022 Feb 13, 2023	SELL	$17.09 - $27.91 $26,130 - $42,674	-1,529 Reduced 3.08%	48,144 $1.31 Million
Q3 2022 Nov 03, 2022	BUY	$15.6 - $21.15 $746,413 - $1.01 Million	47,847 Added 2620.32%	49,673 $858,000
Q2 2022 Aug 12, 2022	SELL	$13.32 - $19.98 $45,621 - $68,431	-3,425 Reduced 65.23%	1,826 $31,000
Q1 2022 May 16, 2022	SELL	$15.24 - $29.75 $586,724 - $1.15 Million	-38,499 Reduced 88.0%	5,251 $89,000
Q4 2021 Feb 14, 2022	SELL	$25.43 - $34.25 $81,503 - $109,771	-3,205 Reduced 6.83%	43,750 $1.19 Million
Q3 2021 Nov 09, 2021	SELL	$28.98 - $39.54 $412,559 - $562,891	-14,236 Reduced 23.26%	46,955 $1.39 Million
Q2 2021 Aug 13, 2021	SELL	$28.5 - $39.37 $644,356 - $890,116	-22,609 Reduced 26.98%	61,191 $2.35 Million
Q1 2021 May 13, 2021	BUY	$30.22 - $45.57 $2.27 Million - $3.43 Million	75,167 Added 870.69%	83,800 $2.56 Million
Q4 2020 Feb 11, 2021	SELL	$23.5 - $52.65 $21,549 - $48,280	-917 Reduced 9.6%	8,633 $329,000
Q3 2020 Nov 12, 2020	SELL	$18.85 - $27.0 $26,408 - $37,827	-1,401 Reduced 12.79%	9,550 $220,000
Q2 2020 Aug 12, 2020	SELL	$9.76 - $25.95 $30,909 - $82,183	-3,167 Reduced 22.43%	10,951 $272,000
Q1 2020 May 13, 2020	BUY	$8.9 - $19.08 $9,006 - $19,308	1,012 Added 7.72%	14,118 $140,000
Q4 2019 Feb 10, 2020	BUY	$11.61 - $17.21 $79,598 - $117,991	6,856 Added 109.7%	13,106 $188,000
Q3 2019 Nov 14, 2019	SELL	$10.01 - $16.87 $12,582 - $21,205	-1,257 Reduced 16.74%	6,250 $87,000
Q2 2019 Aug 14, 2019	BUY	$12.51 - $17.28 $2,414 - $3,335	193 Added 2.64%	7,507 $110,000
Q1 2019 May 15, 2019	BUY	$10.26 - $16.24 $59,867 - $94,760	5,835 Added 394.52%	7,314 $111,000
Q4 2018 Feb 14, 2019	SELL	$9.97 - $15.57 $13,160 - $20,552	-1,320 Reduced 47.16%	1,479 $15,000
Q3 2018 Nov 14, 2018	BUY	$14.99 - $22.14 $41,957 - $61,969	2,799 New	2,799 $45,000

Others Institutions Holding REPL

# of Institutions

149

Shares Held

68M

Call Options Held

52.3K

Put Options Held

80.3K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $709M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account